# Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

> **NCT07144345** · PHASE3 · RECRUITING · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%
- **OTHER:** Vehicle containing excipients only (VEH) without active ingredient
- **DEVICE:** Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E

## Key facts

- **NCT ID:** NCT07144345
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2027-01
- **Final completion:** 2027-04
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07144345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07144345, "Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07144345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*